What is Amarantus BioScience Holdings?
Amarantus BioScience Holdings (AMBS) operates as a specialized biotechnology holding company with a focus on high-unmet-need medical markets. Through its subsidiaries, including Elto Pharma, Cutanogen Corporation, and MANF Therapeutics, the company manages a robust intellectual property portfolio. Key assets include eltoprazine, a small molecule candidate for Parkinson's disease and ADHD, and the Engineered Skin Substitute (ESS) technology, which is currently being prepared for pivotal studies in pediatric burn care. Furthermore, the company's proprietary PhenoGuard discovery engine has yielded the therapeutic protein MANF, which is being investigated for its potential in treating neurodegenerative and ophthalmological conditions such as Retinitis Pigmentosa and Glaucoma. This multi-faceted approach allows Amarantus to diversify its clinical risk while targeting significant therapeutic breakthroughs.
How much funding has Amarantus BioScience Holdings raised?
Amarantus BioScience Holdings has raised a total of $17.2M across 9 funding rounds:
Other Financing Round
$1.1M
Multiple Rounds
$4.3M
Share Placement
$5M
Private Equity
$2.8M
Private Equity
$1M
Share Placement
$3M
Other Financing Round
$100K
Other Financing Round (2012): $1.1M with participation from Undisclosed
Private Equity (2013): $1.3M, investors not publicly disclosed
Debt (2013): $1.4M, investors not publicly disclosed
Private Equity (2013): $1.6M featuring Dominion Capital and International Infusion
Share Placement (2015): $5M backed by Discover Growth Fund
Private Equity (2015): $2.8M, investors not publicly disclosed
Private Equity (2016): $1M led by International Infusion, LLC
Share Placement (2016): $3M, investors not publicly disclosed
Other Financing Round (2017): $100K featuring XPress Group International
Key Investors in Amarantus BioScience Holdings
International Infusion
A venture capital firm focused on disruptive technologies within the life sciences and renewable energy sectors, aiming to solve global challenges through innovative resource allocation.
Dominion Capital
An investment entity associated with large-scale infrastructure and energy utility interests, providing strategic backing for long-term economic and industrial growth initiatives.
Discover Growth Fund
An institutional investment vehicle specializing in growth-stage capital deployments to support the expansion of emerging biotechnology and life science enterprises.
What's next for Amarantus BioScience Holdings?
With the recent influx of capital, Amarantus BioScience Holdings is well-positioned to transition its lead candidates into more advanced clinical phases. The strategic focus remains on the execution of pivotal studies for its regenerative medicine assets and the continued validation of its neurotrophic factor platform. As the company moves forward, the primary objective will be to achieve regulatory milestones that enhance the valuation of its subsidiary assets. Investors will likely monitor the progress of the ESS technology and the clinical outcomes of MANF-based therapies as key indicators of long-term commercial viability. The firm's ability to maintain its research momentum while managing the capital-intensive nature of drug development will be the defining factor in its future market performance.
See full Amarantus BioScience Holdings company page
